Sunday Edition | May 17, 2026 | Covering: May 15 (eve) – May 17, 2026
TL;DR
The macro story this weekend is oil: Brent crude spiked to over $114/bbl as U.S. forces destroyed Iranian vessels in the Strait of Hormuz — the world's most critical oil chokepoint — raising real fears about a supply disruption that the IEA is already calling potentially the largest in history. On the deal front, Big Pharma's buy-vs.-build shift continued to accelerate this week, with Bayer ending a multi-year M&A drought via its $2.45B acquisition of Perfuse Therapeutics (eye disease) and Roche adding AI-powered pathology company PathAI for up to $1.05B — two deals that highlight how pharma dealmakers are hunting for clinical-stage assets before they get expensive. And in a regulatory development worth flagging: the SEC cut the minimum tender offer period for qualifying all-cash deals in half, from 20 to 10 business days — a change that could compress friendly acquisition timelines to as little as 2.5–3 weeks.
TOP 3 DEALS
Bayer to Acquire Perfuse Therapeutics — Up to $2.45B Ophthalmology Pipeline Play
Healthcare / Pharma Strategic M&A Upfront + Milestones
Deal Size (EV)Up to $2.45B ($300M upfront + up to $2.15B in milestones)
StructureCash upfront + development, regulatory, and commercial milestone payments
Target Share PriceN/A (private company)
Lead AssetPER-001 — Phase II small molecule for Glaucoma & Diabetic Retinopathy
Buyer (Bayer) AdvisorsBofA Securities (financial); Baker McKenzie (legal)
Seller (Perfuse) AdvisorsCenterview Partners (financial); Goodwin Procter (legal)
Rationale: Bayer has been under significant financial pressure — its Roundup litigation liability and Monsanto acquisition debt have constrained M&A for years. This deal signals that Bayer's balance sheet has recovered enough to act offensively. Perfuse's lead asset, PER-001, is a Phase II-stage endothelin receptor antagonist targeting two massive, underserved ophthalmic markets: glaucoma (affecting 76M people globally) and diabetic retinopathy (the leading cause of blindness in working-age adults). By acquiring Perfuse now — before Phase III readouts — Bayer gets a clinical-stage asset at a phase-appropriate price rather than paying a full commercial-stage premium later.
Summary: The deal is structured with a modest $300M upfront payment and the bulk of the potential $2.45B tied to clinical, regulatory, and commercial milestones — a structure that protects Bayer if PER-001 fails in later trials while giving Perfuse shareholders participation in the upside if it succeeds. BofA is advising Bayer exclusively; Centerview is advising Perfuse. The deal ends a multi-year Bayer M&A drought — the company hadn't done a significant acquisition since the troubled $63B Monsanto deal in 2018 created years of litigation and financial drag. This is a signal that Bayer's management believes the worst is behind them.
🎯 Why it matters for recruiting: The upfront + milestone structure (often called a "CVR" or contingent value right when it's a tradeable instrument) is everywhere in pharma M&A — it bridges valuation gaps when buyers and sellers disagree on pipeline probability. Know the mechanics: buyers prefer back-end milestones because they only pay if the drug succeeds; sellers prefer upfront cash because milestones are uncertain. When you walk through pharma deal structuring in an interview, this Bayer deal is a clean, current example.
Roche to Acquire PathAI — Up to $1.05B AI-Powered Diagnostics Deal
Healthcare / MedTech Strategic M&A Upfront + Milestones
Deal Size (EV)Up to $1.05B ($750M upfront + up to $300M in milestones)
Structure$750M cash upfront + milestone payments; expected close H2 2026
Target Share PriceN/A (private; VC-backed)
Strategic FitExtends Roche's companion diagnostics platform with AI pathology tools
Buyer (Roche) AdvisorsDavis Polk (legal)
Seller (PathAI) AdvisorsLatham & Watkins (legal)
Rationale: Roche is the world's largest diagnostics company and a major force in precision medicine — its companion diagnostic business (think: the test that tells an oncologist whether a patient's tumor will respond to a specific drug) is a critical moat. PathAI uses AI to analyze pathology slides: it can detect cancers, classify tumor subtypes, and generate data for clinical trial support faster and more accurately than human pathologists working alone. By acquiring PathAI, Roche embeds AI capability into its diagnostics workflow, making its companion diagnostic products faster, cheaper, and more accurate — a durable competitive advantage as precision oncology expands.
Summary: The deal was announced May 7, 2026. Roche will pay $750M upfront and up to $300M in additional milestone payments tied to PathAI's technology hitting development and commercial targets. PathAI is a Boston-based digital pathology startup founded in 2016 and backed by General Atlantic, Tiger Global, and several large healthcare systems. Roche and PathAI had an existing partnership since 2021 (scaled up in 2024), so this acquisition accelerates a relationship already generating shared IP. Davis Polk advises Roche; Latham & Watkins advises PathAI. The deal is expected to close in H2 2026 pending regulatory clearance.
🎯 Why it matters for recruiting: This deal sits at the intersection of three major IB themes right now: AI M&A, healthcare consolidation, and the "buy vs. build" calculus in diagnostics. Roche could have tried to build internal AI pathology tools — but acquiring a startup with 10 years of labeled training data and existing hospital relationships is faster and cheaper than building from scratch. When asked why companies acquire instead of building, this is a crisp, current example to use.
Bullish to Acquire Equiniti from Siris Capital — $4.2B Tokenized Securities Infrastructure Play
FinTech / TMT Strategic M&A Stock + Assumed Debt
Deal Size (EV)~$4.2B total consideration
Structure~$2.35B Bullish (BLSH) stock + ~$1.85B assumed debt; BLSH at $38.48 30-day VWAP
Target Share PriceN/A (private; Siris Capital-owned)
Expected CloseJanuary 2027 (regulatory approvals pending)
Buyer (Bullish) AdvisorsGoldman Sachs (financial)
Seller (Siris Capital) AdvisorsEvercore, FT Partners, Wells Fargo, LionTree (financial)
Rationale: Equiniti is a global transfer agent — the firm that keeps the official shareholder register for thousands of public companies, processes dividend payments, and manages shareholder elections. This is unglamorous but mission-critical financial infrastructure. Bullish, a NYSE-listed crypto exchange backed by Peter Thiel and EOS, is buying Equiniti to rebuild that infrastructure on blockchain rails — enabling "tokenized shares" that would settle in seconds rather than T+2 days, eliminate reconciliation costs between brokers, and serve as the backbone of a blockchain-native capital markets ecosystem.
Summary: Siris Capital, the PE firm that built Equiniti into a global platform, ran a competitive sell-side process with four advisors — Evercore, FT Partners, Wells Fargo, and LionTree — which is an unusual depth of sell-side representation and signals multiple bidders. Goldman Sachs advised Bullish exclusively. The deal is primarily stock consideration ($2.35B) plus Bullish assuming Equiniti's existing debt ($1.85B) — a structure that gives Siris ongoing upside in Bullish's story but also exposes them to BLSH equity risk. Expected close: January 2027, pending what will likely be extensive regulatory review at the intersection of crypto exchanges and securities market infrastructure.
🎯 Why it matters for recruiting: Four sell-side advisors is a signal worth explaining — in a competitive sale process, multiple advisors can help reach a broader universe of buyers, bring sector-specific credibility (FT Partners is the top FinTech boutique), and provide "valuation firepower" through multiple fairness opinions. When you discuss sell-side advisory dynamics in interviews, knowing why a seller might hire four advisors vs. one is a nuanced point that shows you understand deal process, not just deal mechanics.
SECTOR SIGNALS
DEFENSE / AEROSPACE
The Strait of Hormuz situation is the most consequential defense-adjacent development of the weekend: U.S. military forces have engaged Iranian vessels, and Brent crude has spiked to $114/bbl as a result. From an IB angle, this matters because sustained high oil prices and Middle East instability are historically correlated with increased defense procurement budgets, accelerated A&D M&A (particularly in missile systems, electronic warfare, and maritime security), and heightened CFIUS scrutiny on any deal involving defense-adjacent technology. Firms with exposure to naval systems (General Dynamics, L3Harris) have seen stock appreciation on the news. J.P. Morgan Research →
TECH / TMT
President Trump's meetings with President Xi in China this weekend mark the highest-level U.S.-China diplomatic engagement since the Nvidia/H200 chip export saga last week. Markets are watching closely: any progress on tech export restrictions could re-open cross-border TMT M&A deal flow that has been effectively frozen for AI-adjacent hardware. Conversely, deterioration could further chill the already-stressed leveraged loan market for tech companies, where AI disruption fears have already widened spreads on software credits. CNBC →
INDUSTRIALS
Oil at $114/bbl is a double-edged signal for industrials: energy-adjacent businesses (drilling equipment, pipeline infrastructure, LNG terminals) see demand surge, while energy-intensive manufacturers (chemicals, fertilizers, aerospace composites) face margin compression. For M&A, this means the valuation spread between energy-exposed and energy-insulated industrials is widening fast — creating potential dislocation plays for PE buyers who can underwrite through a commodity cycle. The AMETEK/Indicor deal (announced May 6) is a reminder that precision measurement businesses tied to electrification — not hydrocarbons — are the industrials sub-sector attracting strategic premium multiples right now. Al Jazeera →
HEALTHCARE
This week's Bayer/Perfuse and Roche/PathAI deals (see Top 3) confirm that Big Pharma's buy-vs.-build calculus has tilted decisively toward buying. Bayer's re-entry into M&A after a years-long drought is particularly notable: it signals that even litigation-burdened companies can repair their balance sheets and return to offense. Watch for other European pharma majors — Novartis, AstraZeneca, Sanofi — to remain aggressive buyers of U.S. clinical-stage assets through 2026. BioPharma Dive →
M&A
Big regulatory news: the SEC issued an exemptive order in April cutting the minimum tender offer period for qualifying all-cash friendly deals from 20 to 10 business days. Combined with the existing 15-calendar-day HSR waiting period for cash tender offers, well-organized friendly all-cash acquisitions can now potentially close in as little as 2.5–3 weeks from signing. This compresses deal risk windows, reduces the cost of holding financing commitments, and may incrementally favor all-cash structures over mixed cash-and-stock deals. Skadden, Freshfields, and Cooley have all published client alerts calling it a potential "game-changer" for M&A execution. Skadden → | Harvard Law Forum →
MARKET TONE
Markets logged a 7th straight winning week — barely. The S&P 500 eked out gains to extend its streak, but Friday's ~1.2% selloff on Iran/energy fears capped what had been a strong run. The index is up ~8% YTD and ~17% from the March 30 lows. The winning streak is the longest since 2024, but the Iran situation is the most significant macro risk threatening to snap it.
Oil is the dominant variable heading into the week. Brent crude at $114/bbl (up ~6% in a single day at the peak) is a major concern. At these levels, energy costs feed directly into inflation, which complicates the Fed's rate path and could revive rate-hike expectations that markets had largely priced out. The IEA has characterized the Hormuz disruption as the largest potential supply shock in the history of the global oil market.
IG credit remains open; leveraged markets are tightening. Investment-grade spreads (~70bps) continue to support strategic M&A financing for well-rated buyers. But high-yield spreads have widened on the CPI and geopolitical news, and leveraged loans for tech credits are being repriced by lenders wary of AI disruption risk. The bifurcation between IG and HY is the defining credit market story of Q2 2026.
The Fed is on hold — but the calculus is shifting. Energy-driven inflation is the wild card: if $110+ oil persists through the summer, it creates a real risk that CPI re-accelerates and the Fed considers rate hikes rather than cuts. Bond markets had been pricing a September cut; that probability is declining.
Trump-Xi diplomatic talks could move markets meaningfully Monday morning. Any signal of progress on AI chip export restrictions or broader tech trade policy could trigger a significant rally in Nvidia, semiconductors, and AI-exposed names. Deterioration could extend last week's tech selloff.
INTERVIEW ANGLE
Concept: The SEC's New 10-Day Tender Offer Rule — How Regulatory Changes Affect Deal Execution
News hook: In April 2026, the SEC cut the minimum tender offer period for qualifying all-cash, friendly acquisitions from 20 to 10 business days — a change that could compress sign-to-close timelines for public company takeouts to as little as 2.5–3 weeks.
A tender offer is one of two ways to acquire a public company: instead of a merger vote (which takes months), the buyer goes directly to shareholders and offers to buy their shares at a premium, bypassing or supplementing the board approval process. The SEC previously required the offer to remain open for at least 20 business days.
Cutting to 10 business days matters because it reduces the window during which a "deal spread" exists — the gap between the target's trading price and the offer price. A shorter window means less time for a competing bidder to emerge, less financing cost for the acquirer, and less market risk (if stocks move sharply, a longer open period is riskier for both sides).
The new rule only applies to negotiated, friendly, all-cash, fixed-price deals for U.S. public companies — not hostile bids, stock deals, or private company acquisitions. So it's most relevant to strategic M&A where both boards are aligned from day one.
In practice, this change favors larger, well-capitalized strategic buyers who can move quickly and don't need complex financing arrangements. PE sponsors financing with debt may not benefit as much, since their financing process (syndication, bank commitment letters) often takes longer than the tender offer window anyway.
How to bring it up: If asked about recent regulatory developments in M&A, you could say: "One thing I've been following is the SEC's April exemptive order cutting tender offer periods to 10 business days for qualifying all-cash deals. It's interesting because it compresses deal risk for buyers and reduces the window for competing bids — which net-net probably benefits strategic acquirers with strong balance sheets more than PE sponsors who still need time to syndicate debt."